RENESE-R
Clinical safety rating
cautionComprehensive clinical and safety monograph for RENESE-R (RENESE-R).
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
| Metabolism | Metabolized by liver (CYP450) to active metabolite; excreted in feces (65%) and urine (35%). |
| Excretion | Renal: 50% unchanged; fecal: 0%; biliary: 0% |
| Half-life | Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing |
| Protein binding | 80-90% bound to plasma proteins, primarily albumin |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution mainly in extracellular fluid |
| Bioavailability | Oral: 70-80% |
| Onset of Action | Oral: 1-2 hours; IV: not applicable |
| Duration of Action | Oral: 22-24 hours; note: diuretic effect may last up to 24 hours |
| Molecular Weight | 347.51 |
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 2.5 mg orally once daily; use caution due to increased sensitivity to electrolyte disturbances and hypotension. |
| 1st trimester | Risk based on animal studies; no adequate human studies. Possible association with neural tube defects if folate deficiency is worsened. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal hypotension, decreased placental perfusion, and oligohydramnios. Monitor fetal growth and amniotic fluid volume. |
| 3rd trimester | May cause fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal effects (hypoglycemia, electrolyte disturbances). Avoid in pregnancy-induced hypertension due to maternal hypovolemia. |
Clinical note
Comprehensive clinical and safety monograph for RENESE-R (RENESE-R).
| Placental transfer | Crosses placenta; may cause fetal and neonatal effects. Degree of transfer not precisely quantified but thought to be moderate. |
| Breastfeeding | Excreted into human milk in small amounts; potential for serious adverse reactions in nursing infants (electrolyte imbalance, thrombocytopenia). Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating | L4 |
| Teratogenic Risk | Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults. Because thiazides cross the placental barrier and appear in cord blood, use during the third trimester may cause electrolyte disturbances, hypoglycemia, and other effects. The drug should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus. |
| Fetal Monitoring | Maternal monitoring: Blood pressure, serum electrolytes (especially potassium, sodium), blood glucose, and renal function. Fetal monitoring: Ultrasound to assess growth and amniotic fluid volume due to potential for oligohydramnios. Fetal heart rate monitoring should be considered in third trimester if signs of fetal distress are present. |
| Fertility Effects | No specific studies have been conducted on polythiazide's effects on fertility. Thiazide diuretics have been associated with reversible oligospermia and erectile dysfunction in males. In females, thiazides have not been directly linked to impaired fertility, but electrolyte disturbances may theoretically affect ovulatory function. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
AnuriaSulfonamide allergyHepatic coma or precomaSevere electrolyte depletionHypersensitivity to thiazides or sulfonamides
| Precautions | May cause hypokalemia and hypomagnesemia, Can precipitate hyperuricemia and gout, May increase serum calcium, Use with caution in diabetes (may increase blood glucose), Photosensitivity reactions reported, Sulfonamide allergy: possible cross-reactivity |
| Food/Dietary | Avoid excessive salt intake as it can reduce the antihypertensive effect. Limit alcohol consumption, which may enhance orthostatic hypotension. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but monitor potassium levels as thiazides can cause hypokalemia; supplement potassium if indicated. Grapefruit juice has no known interaction with this combination. |
| Clinical Pearls | Renese-R is a fixed-dose combination of polythiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid antihypertensive. Watch for hypokalemia, especially in patients on digoxin. Reserpine can cause significant bradycardia and depression; avoid in patients with history of depression. Discontinue at least 2 weeks before electroconvulsive therapy. Monitor for orthostatic hypotension, especially when used with other antihypertensives. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination. · Avoid alcohol and standing up quickly from lying or sitting positions to prevent dizziness. · Report symptoms of depression, severe drowsiness, or slow heartbeat to your doctor immediately. · You may need to have regular blood tests to monitor potassium levels and kidney function. · This medication can cause increased sensitivity to sunlight; use sunscreen and protective clothing. · Do not stop taking this drug abruptly without consulting your doctor. |
Loading safety data…